Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Treasury Shares: 2010-2025

Historic Treasury Shares for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Dec 2016 value amounting to $2.9 million.

  • Lineage Cell Therapeutics' Treasury Shares fell 83.97% to $2.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was $2.9 million, marking a year-over-year decrease of 83.97%. This contributed to the annual value of $2.9 million for FY2016, which is 83.97% down from last year.
  • Lineage Cell Therapeutics' Treasury Shares amounted to $334,000 in Q3 2025, which was down 0.00% from $334,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Treasury Shares high stood at $939,000 for Q4 2022, and its period low was $334,000 during Q1 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Treasury Shares averaged around $492,556, with its median value being $501,000 (2024).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Treasury Shares soared by 413.81% in 2013, and later crashed by 85.47% in 2016.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Treasury Shares stood at $8.4 million in 2012, then surged by 413.81% to $43.0 million in 2013, then crashed by 53.78% to $19.9 million in 2014, then dropped by 9.34% to $18.0 million in 2015, then crashed by 83.97% to $2.9 million in 2016.
  • Its Treasury Shares stands at $2.9 million for Q4 2016, versus $2.9 million for Q3 2016 and $2.9 million for Q2 2016.